Adaptimmune Therapeutics PLC

Recent News

• Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors

  - 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development planned in ovarian (SURPASS-3), urothelial, and head & neck cancers -- Across all tumor types in the SURPASS trial, responses observed in five solid tumor types in 43 heavily pre-treated patients with an ORR of 33% -- Across non-sarcoma tumors, significantly higher response rates compared with the first-generation MAGE-A4 targeted...

  2022-09-09 7:00 AM EDT
• Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials

  - Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will provide an update on its Phase 1 SURPASS trial data and outline future plans for the SURPASS family of trials during a live virtual event to be held on Friday, September 9th, at 8 a.m. EDT (1 p.m. BST). You can...

  2022-08-25 8:00 AM EDT
• Adaptimmune Reports Second-Quarter Financial Results and Business Update

  - Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phase 1 SURPASS trial at the September ESMO 2022 Congress - - Quarterly call to be held today, August 4, 2022, at 8:00 a.m. EDT (1:00 p.m. BST) -Philadelphia, Pennsylvania, and Oxford, United Kingdom--(Newsfile Corp. - August 4, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to...

  2022-08-04 7:30 AM EDT
• Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022

  Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2022, before the US markets open on Thursday, August 4, 2022. Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) that same day.The press release will be available in the...

  2022-07-21 8:00 AM EDT
• Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track

  - Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) -- Responses occurred across subgroups, with greater response rates associated with lower baseline tumor burden, fewer prior lines of therapy, and higher MAGE-A4 expression -- Afami-cel demonstrated a favorable benefit:risk profile -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 26, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, presented pooled analyses from its...

  2022-05-26 5:00 PM EDT